Clinical trials
Nasopharyngeal Carcinoma clinical trials
Below are recruiting nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 168 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07232680Recruiting
Immune profile study for nasopharyngeal cancer patients
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Taoyuan City, TaiwanAges 18 years+ - NCT05674305RecruitingPhase 3
Tested radiation alone vs added chemotherapy for EBV-negative after treatment
This Phase 3 trial compares giving radiation alone versus giving radiation at the same time as chemotherapy for nasopharyngeal cancer. It focuses on people whose EBV test becomes undetectable after one cycle of chemotherapy, to see which approach works best and is safest.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06852638RecruitingPhase 2
PET imaging for kidney cancer, lymphoma, and NPC
This study tests a new way to detect tumors by using a special injection that makes cancer cells visible on a PET scan. It may help people with renal cancer (especially clear cell type), lymphoma, or nasopharyngeal cancer.
ShanghaiAges 18–80 - NCT07085234RecruitingPhase 2
New drug combo before radiation for advanced nasopharyngeal cancer
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy before standard radiation for advanced nasopharyngeal cancer. It aims to shrink tumors and improve outcomes.
Xiamen, FujianAges 18–65 - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT06282497Recruiting
New radiation technique to reduce dry mouth in nasopharyngeal cancer
This trial compares a new radiation technique designed to reduce dry mouth (xerostomia) with standard radiation for people with nasopharyngeal cancer. It aims to see if the new approach can protect saliva glands while still treating the cancer effectively.
Zhongshan, GuangdongAges 18–70 - NCT07559877RecruitingPhase 3
Chlorhexidine spray to prevent radiation skin damage in throat cancer
This study tests whether a chlorhexidine spray (an antiseptic liquid) can prevent or reduce skin damage caused by radiation therapy in people being treated for nasopharyngeal cancer (cancer in the back of the nose/throat). Radiation dermatitis—painful redness and irritation of the skin—is a common side effect, and this spray may help protect your skin during treatment.
Nanchang, JiangxiAges 18–75 - NCT07392320RecruitingPhase 2
Immunotherapy or chemo pills after chemoradiation for high-risk nasopharyngeal cancer
This trial compares two options—a type of immunotherapy or a chemotherapy pill (capecitabine)—as maintenance treatment after standard chemoradiation for high-risk nasopharyngeal cancer. It aims to see which helps prevent the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT03919552RecruitingPhase 3
Chemoradiation with two cisplatin or carboplatin plans for nasopharyngeal cancer
This Phase 3 trial compares two chemotherapy-and-radiation combinations (cisplatin-based vs carboplatin-based) for locally advanced nasopharyngeal cancer that has not spread to distant organs. It may help researchers find which plan works best while balancing safety and effectiveness.
Guangzhou, GuangdongAges 18–64 - NCT04544969Recruiting
Testing blood markers to guide chemo for metastatic nasopharyngeal cancer
This study looks at special blood markers (CTCs) to see how sensitive your cancer is to chemotherapy and to better predict how well treatment may work. If you have metastatic nasopharyngeal cancer and can’t have local treatment, this may help match you to more effective chemo plans.
Guangzhou, GuangdongAges 18–70 - NCT04547673Recruiting
Test an endoscopy camera tool to help diagnose throat cancer
This study checks an “intelligent” camera used during a nose-and-throat exam to improve how nasopharyngeal cancer is diagnosed. If you are eligible, your care team will compare how well the tool identifies the condition.
Guangzhou, GuangdongAges 18 years+ - NCT04830267RecruitingPhase 2
Camrelizumab plus focused radiation for recurrent metastatic nasopharyngeal cancer
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05340491RecruitingPhase 3
Radiation plus immunotherapy for repeat nasopharyngeal cancer
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Guangzhou, GuangdongAges 18–70 - NCT05514275RecruitingPhase 2
Radiation plus endostatin and capecitabine for nasopharyngeal cancer
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
Hangzhou, ZhejiangAges 18–65 - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT05941741RecruitingPhase 3
Tested low-dose radiation plus cadonilimab for nasopharyngeal cancer
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
Guangzhou, GuangdongAges 18–70 - NCT05955105RecruitingPhase 1/Phase 2
ILB-2109 plus toripalimab for advanced solid cancers
This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.
Jinan, ShandongAges 18–80 - NCT06017895Recruiting
Doxepin rinse for severe swallowing pain during throat radiation
This trial tests a medicated mouth rinse (doxepin) to ease severe pain when swallowing, caused by radiation therapy for nasopharyngeal cancer. It aims to help patients who are currently receiving radiation and have mouth or throat sores.
Guangzhou, GuangdongAges 18 years+ - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06059261RecruitingPhase 2
Envafolimab plus chemoradiation and endostatin for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (envafolimab) with standard chemoradiation and a drug that blocks blood vessel growth (endostatin) for people with advanced nasopharyngeal cancer that hasn't been treated before. The goal is to see if this combination works better than the usual treatment.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 168 recruiting nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Nasopharyngeal Carcinoma (NPC)
- Locally Advanced Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma AJCC v8
- Metastatic Nasopharyngeal Carcinoma
- Stage III Nasopharyngeal Carcinoma AJCC v8
- Nasopharyngeal Carcinoma by AJCC V8 Stage
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.